Apolipoprotein E structure: insights into function, Trends Biochem. Sci, vol.31, pp.445-454, 2006. ,
Apolipoprotein E in Alzheimer's disease and other neurological disorders, Lancet Neurol, vol.10, pp.241-252, 2011. ,
Gene dose of apolipoprotein-E type-4 allele and the risk of Alzheimers-disease in late-onset families, Science, vol.261, pp.921-923, 1993. ,
Human apolipoprotein E: The Alzheimer's disease connection, FASEB J, vol.10, pp.1485-1494, 1996. ,
Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease, Neurosci. Lett, vol.223, pp.29-32, 1997. ,
Plasma apolipoprotein E and Alzheimer disease risk The AIBL study of aging, Neurology, vol.76, pp.1091-1098, 2011. ,
Apolipoprotein-E (Apoe) polymorphism and its influence on Apoe concentrations in the cerebrospinal-fluid in Finnish patients with Alzheimers-disease, Human Gen, vol.95, pp.39-42, 1995. ,
Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease, Neurosci. Lett, vol.259, pp.33-36, 1999. ,
Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study, Neurosci. Lett, vol.248, pp.21-24, 1998. ,
Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians, Int. Psychogeriatrics, vol.15, pp.40-41, 2003. ,
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease, Nat. Biotechnol, vol.29, pp.635-643, 2011. ,
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins, Mol. Cell. Proteomics, vol.5, pp.573-588, 2006. ,
Options and considerations when selecting a quantitative proteomics strategy, Nat. Biotechnol, vol.28, pp.710-721, 2010. ,
Perspectives of targeted mass spectrometry for protein biomarker verification, Curr. Opinion Chem. Biol, vol.13, pp.518-525, 2009. ,
Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap, Anal. Chem, vol.78, pp.5762-5767, 2006. ,
Targeted proteomic strategy for clinical biomarker discovery, Mol. Oncol, vol.3, pp.33-44, 2009. ,
On the development of plasma protein biomarkers, J. Proteome Res, vol.10, pp.5-16, 2011. ,
The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification, Clin. Chem, vol.56, pp.212-222, 2010. ,
Protein biomarker discovery and validation: the long and uncertain path to clinical utility, Nat. Biotechnol, vol.24, pp.971-983, 2006. ,
A targeted proteomics-based pipeline for verification of biomarkers in plasma, Nat. Biotechnol, vol.29, pp.625-108, 2011. ,
Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?, Clin. Chem, vol.54, pp.1749-1752, 2008. ,
The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline, Proteomics Clin. Appl, vol.2, pp.1386-1402, 2008. ,
Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry, Clin. Chem, vol.54, pp.1796-1804, 2008. ,
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution, Mol. Cell. Proteomics, vol.6, pp.2212-2229, 2007. ,
Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests, Mol. Cell. Proteomics, vol.8, pp.1006-1015, 2009. ,
Evaluation of different multidimensional LC-MS/MS pipelines for isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic analysis of potato tubers in response to cold storage, J. Proteome Res, vol.10, pp.4647-4660, 2011. ,
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry, Clin. Chem, vol.55, pp.1108-1117, 2009. ,
Platform for establishing inter laboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays, J. Proteome Res, vol.9, pp.6678-6688, 2010. ,
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma, Nat. Biotechnol, vol.27, pp.633-85, 2009. ,
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution, Mol. Cell. Proteomics, vol.8, pp.2339-2349, 2009. ,
Inter-laboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma, Mol. Cell. Proteomics, vol.11, 2012. ,
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance, Mol. Cell. Proteomics, vol.9, pp.242-254, 2010. ,
Systematic quantification of peptides/proteins in urine using selected reaction monitoring, Proteomics, vol.11, pp.1135-1147, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02619035
Selected reaction monitoring applied to proteomics, J. Mass Spectrom, vol.46, pp.298-312, 2011. ,
Selected reaction monitoring for quantitative proteomics: a tutorial, Mol. Syst. Biol, vol.4, p.222, 2008. ,
Mass spectrometry based targeted protein quantification: methods and applications, J. Proteome Res, vol.8, pp.787-797, 2009. ,
Quantification and significance of protein oxidation in biological samples, Drug Metab. Rev, vol.32, pp.307-326, 2000. ,
Oxidation of methionyl residues in proteins -tools, targets, and reversal, Free Radical Biol. Med, vol.18, pp.93-105, 1995. ,
Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS, Proc. Natl. Acad. Sci. U. S. A, vol.100, pp.6940-6945, 2003. ,
Accurate quantification of cardiovascular biomarkers in serum using Protein Standard Absolute Quantification (PSAQ TM ) and selected reaction monitoring, Mol. Cell. Proteomics, vol.11, 2012. ,
Multiple reaction monitoringbased, multiplexed, absolute quantitation of 45 proteins in human plasma, Mol. Cell. Proteomics, vol.8, pp.1860-1877, 2009. ,
A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin, J. Proteome Res, vol.9, pp.5422-5437, 2010. ,
Tyrosine-lipid peroxide adducts from radical termination: para coupling and intramolecular diels-alder cyclization, J. Am. Chem. Soc, vol.132, pp.17490-17500, 2010. ,
APOE epsilon 3/epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis, Exp. Neurol, vol.183, pp.249-253, 2003. ,
Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry, Anal. Biochem, vol.395, pp.116-118, 2009. ,
Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquidchromatography-multiple-reaction-monitoring mass spectrometry, Clin. Chem, vol.56, pp.1804-1813, 2010. ,
Redox proteomics of protein-bound methionine oxidation, Mol. Cell. Proteomics, vol.10, 2011. ,
Four stage liquid chromatographic selection of methionyl peptides for peptide-centric proteome analysis: The proteome of human multipotent adult progenitor cells, J. Proteome Res, vol.5, pp.1415-1428, 2006. ,
Chromatographic isolation of methionine-containing peptides for gel-free proteome analysis -Identification of more than 800 Escherichia coli proteins, Mol. Cell. Proteomics, vol.1, pp.896-903, 2002. ,
Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures, Clin. Chem, vol.58, pp.777-781, 2012. ,
A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry, Rapid Commun. Mass Spectrom, vol.26, pp.101-108, 2012. ,
Comparison of standard-and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins, Anal. Bioanal. Chem, 2012. ,
Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants, Proteomics, vol.11, pp.3633-3641, 2011. ,
Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA), J. Proteome Res, vol.3, pp.235-244, 2004. ,
Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry, Mol. Cell. Proteomics, vol.10, 2011. ,
Heritabilities of apolipoprotein and lipid levels in three countries, Twin Res, vol.5, pp.87-97, 2002. ,
Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels, J. Neurosci, vol.28, pp.11445-11453, 2008. ,
Combined association and linkage analysis applied to the APOE locus, Genetic Epidemiol, vol.26, pp.328-337, 2004. ,
Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms, J. Clin. Lab. Anal, vol.14, pp.260-264, 2000. ,
Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors, J. Lipid Res, vol.37, pp.1316-1324, 1996. ,
Isotope-labeled protein standards, Mol. Cell. Proteomics, vol.6, pp.2139-2149, 2007. ,
The importance of plasma concentration in addition apolipoprotein E to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe, Eur. J. Human Gen, vol.10, pp.841-850, 2002. ,
URL : https://hal.archives-ouvertes.fr/hal-00176672
Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project, Atherosclerosis, vol.152, pp.475-488, 2000. ,
Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene, Febs Letts, vol.421, pp.105-108, 1998. ,
Ps within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels, J. Alzheimers Dis, vol.13, pp.255-266, 2008. ,
Pronounced impact of Th1/E47cs mutation compared with ?491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease, Human Mol. Gen, vol.7, pp.1511-1516, 1998. ,
Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations -the ECTIM Study, Human Mol. Gen, vol.9, pp.57-61, 2000. ,
Variation at the APOE-491 promoter locus is associated with altered brain levels of apolipoprotein E, Mol. Psychiatry, vol.7, pp.886-890, 2002. ,
The ?491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease, Neuroreport, vol.10, pp.879-882, 1999. ,
A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia, Nat. Gen, vol.18, pp.69-71, 1998. ,
Apolipoprotein gene E4 allele promoter polymorphisms as risk factors for Alzheimer's disease, Psychiatric Gen, vol.15, pp.271-275, 2005. ,
Neuronal specific regulatory elements in apolipoprotein E gene proximal promoter, Neuroreport, vol.16, pp.1027-1030, 2005. ,
The ?491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism, Neurosci. Lett, vol.252, pp.95-98, 1998. ,
Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease, Neurology, vol.55, pp.1644-1649, 2000. ,
Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: Patterns of linkage disequilibrium and disease/marker association, Genomics, vol.89, pp.655-665, 2007. ,
Genetic heterogeneity of Alzheimer's disease: Complexity and advances, Psychoneuroendocrinology, vol.32, pp.62-70, 2007. ,
Genetics of Alzheimer's disease: new evidences for an old hypothesis?, Curr. Opinion Gen. Develop, vol.21, pp.295-301, 2011. ,
Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice, J. Neurosci, vol.29, pp.6771-6779, 2009. ,
Human apolipoprotein E4 alters the amyloid-beta 40 : 42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model, J. Neurosci, vol.25, pp.2803-2810, 2005. ,
Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease, Neurobiol. Disease, vol.9, pp.305-318, 2002. ,
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A, vol.97, pp.2892-2897, 2000. ,
, Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects, vol.75, pp.1976-1981, 2010.
APOE Predicts Amyloid-Beta but Not Tau Alzheimer Pathology in Cognitively Normal Aging, Ann. Neurol, vol.67, pp.122-131, 2010. ,
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.6820-6825, 2009. ,
Cerebrospinal fluid betaamyloid(1-42) and tau in control subjects at risk for Alzheimer's disease: The effect of APOE epsilon 4 allele, Biol. Psychiatry, vol.56, pp.670-676, 2004. ,
Cerebrospinal-fluid apolipoprotein-E is reduced in Alzheimers-disease, Neuroreport, vol.5, pp.2534-2536, 1994. ,
Clinical Relevance of the Quantification of Apolipoprotein-E in Cerebrospinal-Fluid, Clin. Chim. Acta, vol.196, pp.167-176, 1991. ,
Age-dependent decline in the apolipoprotein e level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease, Eur. Neurol, vol.43, pp.161-169, 2000. ,
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid, Neurochem. Res, vol.25, pp.511-517, 2000. ,
The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 42, apolipoprotein E and transthyretin in human cerebrospinal fluid, Clin. Biochem, vol.31, pp.409-415, 1998. ,
Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform, Dementia, vol.7, pp.273-278, 1996. ,
Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease, Neurosci. Letts, vol.212, pp.91-94, 1996. ,
Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: Impact on non-Alzheimer's dementia?, J. Neural Trans. Supplement, vol.49, pp.259-266, 1996. ,
Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects -Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions, Arch. Neurol, vol.54, pp.267-272, 1997. ,
Cerebrospinal fluid apo E and apo A-I concentrations in early and late-onset Alzheimer's disease, Neurosci. Letts, vol.231, pp.175-178, 1997. ,
ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models, Science, vol.335, pp.1503-1506, 2012. ,